Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.82 |
| ▸ | GALR3 | O60755 | 1/20 | 0.82 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.82 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.82 |
| ▸ | HTT | P42858 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.82 |
| ▸ | ADK | P55263 | 12/20 | 0.72 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.68 |
| ▸ | CDK1 | P06493 | 1/20 | 0.62 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.60 |
| ▸ | STAT6 | P42226 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sangivamycin SCHEMBL6731962 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL10262607 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL2786660 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL29897938 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL15107357 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL12284269 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL13065171 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL14227089 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL29639760 | 1.00 | NPC1 (0.82) | NPC1GALR3S1PR4ALDH1A1MAPT | |
| Sangivamycin SCHEMBL20141962 | 0.99 | NPC1 (0.80) | NPC1GALR3S1PR4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 641 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086871-A1 | ANTI-AGEING COMPOUNDS, USES THEREFOR, METHOD FOR IDENTIFYING, AND COMPOSITIONS CONTAINING | Centre for Translational Stem Cell Biology Limited (CN) | 2026-04-30 | — | — | WO | claimed |
| US-20240418701-A1 | SINGLE MOLECULE IDENTIFICATION WITH A REACTIVE HETERO-NANOPORE | NANJING UNIVERSITY (CN) | 2024-12-19 | — | — | US | claimed |
| EP-4413379-A1 | SINGLE MOLECULE IDENTIFICATION WITH A REACTIVE HETERO-NANOPORE | Nanjing University (CN) | 2024-08-14 | — | — | EP | claimed |
| US-20230413828-A1 | BIOHERBICIDES FOR CONTROLLING ONE OR MORE PLANT SPECIES | AGROSPHERES, INC. | 2023-12-28 | — | — | US | claimed |
| US-11779585-B2 | Method for treating coronavirus infections | OYAGEN, INC. (US) | 2023-10-10 | — | — | US | claimed |
| EP-4247160-A1 | BIOHERBICIDES FOR CONTROLLING ONE OR MORE PLANT SPECIES | Agrospheres, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| US-20230285434-A1 | METHOD FOR TREATING ARENAVIRIDAE INFECTIONS | OYAGEN, INC. | 2023-09-14 | — | — | US | claimed |
| US-11738025-B2 | Method for treating coronavirus infections | OYAGEN, INC. (US) | 2023-08-29 | — | — | US | claimed |
| US-11725227-B2 | Devices and methods for examining drug effects on microorganisms | ESSENLIX CORPORATION (US) | 2023-08-15 | — | — | US | claimed |
| US-20230233591-A1 | METHOD FOR TREATING POXVIRIDAE INFECTIONS | OYAGEN, INC. | 2023-07-27 | — | — | US | claimed |
| WO-1992017185-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1992-10-15 | — | — | WO | claimed |
| WO-1992005200-A1 | XENOBIOTIC-ANTIBODY CONJUGATES | CHEMEX PHARMACEUTICALS, INC. (US) | 1992-04-02 | — | — | WO | claimed |
| WO-1992000988-A1 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | BODOR NICHOLAS S (US) | 1992-01-23 | — | — | WO | claimed |
| EP-0262696-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1988-04-06 | — | — | EP | claimed |
| EP-0224283-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-06-03 | — | — | EP | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0221588-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-13 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285434-A1 | METHOD FOR TREATING ARENAVIRIDAE INFECTIONS | MPO, LIPA, CAT | NPC1 140/4885GALR3 1885/4885S1PR4 1907/4885 |
| US-11779585-B2 | Method for treating coronavirus infections | ACE2, ACE, SARS1 | NPC1 283/4885GALR3 4089/4885S1PR4 3617/4885 |
| US-11738025-B2 | Method for treating coronavirus infections | ACE2, ACE, SARS1 | NPC1 248/4885GALR3 4095/4885S1PR4 3488/4885 |
| US-20230233591-A1 | METHOD FOR TREATING POXVIRIDAE INFECTIONS | ITPA, VAC14, MAVS | NPC1 2854/4885GALR3 4434/4885S1PR4 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.